CD274 and neoplasm: In the case of PD-L1 and SIGLEC-15, one acts at the T-cell–antigen-presenting cell/tumor cell interface (through PD-1/PD-L1 inhibitory signaling), while the other can influence myeloid cells and their interaction with T cells.